Comparative Pharmacology
Head-to-head clinical analysis: DANTROLENE SODIUM versus ROBAXISAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DANTROLENE SODIUM versus ROBAXISAL.
DANTROLENE SODIUM vs ROBAXISAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dantrolene sodium dissociates the excitation-contraction coupling in skeletal muscle by inhibiting calcium release from the sarcoplasmic reticulum via ryanodine receptor blockade.
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is not fully understood, but it is believed to involve general central nervous system depression and inhibition of polysynaptic reflexes in the spinal cord. Aspirin inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis, which provides analgesic and anti-inflammatory effects, and also irreversibly inhibits platelet aggregation.
25 mg orally once daily for 7 days; then 25 mg three times daily for 7 days; then 50 mg three times daily for 7 days; then 100 mg three times daily. Maximum daily dose: 400 mg. For malignant hyperthermia: 1 mg/kg intravenously, may repeat up to cumulative dose of 10 mg/kg.
Oral: 2 tablets (methocarbamol 750 mg / aspirin 650 mg) 4 times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 8-10 hours in adults; may be prolonged to 12-15 hours in elderly or patients with hepatic impairment. Steady-state achieved in 3-4 days.
Methocarbamol: 1.0–2.0 hours (prolonged in renal impairment); guaifenesin: approximately 1 hour.
Primarily hepatic metabolism; approximately 25% excreted in urine as metabolites, 45-50% in feces via bile; less than 1% unchanged in urine.
Methocarbamol: renal (primarily as glucuronide and sulfate conjugates, with <2% unchanged); guaifenesin: renal (metabolites, <1% unchanged). No significant biliary/fecal elimination.
Category A/B
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant